Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Messing with a stock
View:
Post by steamfitter on Jan 20, 2021 8:04am

Messing with a stock

Put all kinds of things in front of news. Constantly push none info infront of interested investors till they turn away. Big pharmaceutical companies want to bury this news of a cure so they continue pushing cancer drugs that sustain but not cure. JMPoint of view. If they can bankrupt the company the cure goes away. Not one major news agency in the United States or Canada have brought it forward on 6 oclock news. Not good for surgery either.
Comment by Oden6570 on Jan 20, 2021 8:25am
 I fully believe Skier is a Theralase stockhouse troll. For years now he continues with his political BS stirring up investors whom think differently than him. He clutters the board with non TLT related BS. Those that respond to him may in fact be part of the BJ basement boys alumni.  It is up to real TLT investors to police this board going fwd. I ask again that you PLEASE stop the ...more  
Comment by skier59 on Jan 20, 2021 8:40am
Saving the USA and North America, and the World, was an honor these past 4 years to help ensure Trump never got a second term. I'm not a troll, just a pain in the butt to the Trump Zombies.
Comment by Sunvalley on Jan 20, 2021 8:31am
And they hire people like skier and his ilk to continuously deflect and agitate by  belabouring other subjects like politics and changing the focus from what should be the subject at hand
Comment by skier59 on Jan 20, 2021 8:37am
Just goes to show how stupid you are, and can't accept the facts. I've never been paid for any one post. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250